Evidence map›Paper›PMID 34432370›Full record

ArticleJournal of cellular and molecular medicine2021

Chalcomoracin prevents vitreous-induced activation of AKT and migration of retinal pigment epithelial cells.

Haote Han, Yanhui Yang, Bing Liu, Jingkui Tian, Lijun Dong, Hui Qi, Wei Zhu, Jiantao Wang, Hetian Lei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Haote HanInstitute of Cancer and Basic Medicine, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0003-4177-5235
Yanhui YangSchool of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.
Bing LiuGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Jingkui TianInstitute of Cancer and Basic Medicine, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Lijun DongShenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, China.
Hui QiShenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, China.
Wei ZhuInstitute of Cancer and Basic Medicine, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Jiantao WangShenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, China.
Hetian LeiShenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, China.ORCID 0000-0003-4091-1936
Jinan University · CNZhejiang Cancer Hospital · CNGuangzhou Medical University · CNMassachusetts Eye and Ear Infirmary · USNingxia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal pigment epithelial (RPE) cells are the major cell type in the epi- or sub-retinal membranes in the pathogenesis of proliferative vitreoretinopathy (PVR), which is a blinding fibrotic eye disease and still short of effective medicine. The purpose of this study is to demonstrate whether Chalocomoracin (CMR), a novel purified compound from fungus-infected mulberry leaves, is able to inhibit vitreous-induced signalling events and cellular responses intrinsic to PVR. Our studies have revealed that the CMR IC50 for ARPE-19 cells is 35.5 μmol/L at 72 hours, and that 5 μmol/L CMR inhibits vitreous-induced Akt activation and p53 suppression; in addition, we have discovered that this chemical effectively blocks vitreous-stimulated proliferation, migration and contraction of ARPE-19 cells, suggesting that CMR is a promising PVR prophylactic.

Indexed as

AnimalsBenzofuransCell LineCell MovementCell ProliferationCells, CulturedEpithelial CellsHumansProto-Oncogene Proteins c-aktRabbitsRetinal Pigment EpitheliumSignal TransductionTumor Suppressor Protein p53Vitreous BodyBenzofuranschalcomoracinProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Aktchalocomoracincontractionmigrationp53proliferationproliferative vitreoretinopathyvitreous

Identifiers

PMID34432370
PMCPMC8500972
OpenAlexW3195993618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.